Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

MrLucky123 Sep. 1 at 2:57 PM

$OMER continues to trade very well

0 · Reply

Polanc Sep. 1 at 1:52 PM

$OMER it wants to go up!

1 · Reply

StatsGuru Sep. 1 at 10:49 AM

$OMER today is going to be bulls day!!

0 · Reply

Phase3 Sep. 1 at 3:27 AM

$OMER .......

0 · Reply

uptech Sep. 1 at 1:30 AM

$OMER You have to shoot against the algos if you want to day-trade. Do not believe any service that is selling you trades imo. Use your gut. Go against the flow and be quick. I gave that up years ago and now I only swing trade. That only works if you understand psychology. Good luck

0 · Reply

Phase3 Sep. 1 at 12:30 AM

$OMER I must've blocked those whining about some register ringing within the company as I'm just seeing the ' nothing burger' posts. Not even worth it imho. Strong finish today, I want 1880 to become support tomorrow...👍😎

1 · Reply

MrLucky123 Aug. 31 at 10:24 PM

$OMER brutal month for the shorts, more to come. Come on GD let's get that NVO $ and EMA

1 · Reply

uptech Aug. 31 at 9:28 PM

$OMER Have you been around the market for a while? Every time a stock has a good run, you will always have insiders/directors etc selling a few shares. Either they are old and want to go on a cruise and/or gift money to grandchildren, or they are middle aged and want to pay for kids' college or buy/build a new house. This is totally normal. What you do not want to see is a CEO dumping huge amounts of stock. How many shares has Greg sold?? Move along. Nothing to see here. The institutions are on the bid.

1 · Reply

TRYII Aug. 31 at 9:02 PM

$OMER Guys, most of these insiders have sat on severely depressed options / stock for a long, long time and now they are outside of a "Quiet Period", they are finally able to, many after years, sell some shares / options that were mainly parts of compensation packages. These sales have NOTHING to do with anything else. Sometimes it's just that simple so stop with the crazy scare tactics and Be Well!

0 · Reply

StockMktGuru Aug. 31 at 8:51 PM

$OMER He has filed to sell upto 25K shares in the next 90 days. Does he expect the SP to rise a lot in 90 days? What would you do if you expected the SP to rise a lot in 90 days? He will still own ~48K shares assuming he sells all 25K. Not sold YET, read the filing.

2 · Reply

Omeros reports Q2 adjusted EPS 2c vs (24c) last year

Aug 12, 2026, 4:30 PM EDT - 19 days ago

Omeros Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 19 days ago

Omeros Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 19 days ago

Omeros Quarterly report: Q2 2026

Aug 12, 2026, 4:02 PM EDT - 19 days ago

Omeros Corporation Reports Second Quarter 2026 Financial Results

Aug 10, 2026, 8:00 AM EDT - 22 days ago

Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

2026-08-03T12:41:41.000Z - 4 weeks ago

Omeros grants new technology add-on payment status to Yartemlea

Aug 3, 2026, 8:30 AM EDT - 4 weeks ago

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

2026-07-27T14:15:25.000Z - 5 weeks ago

AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright

AZN

2026-07-27T14:15:17.000Z - 5 weeks ago

Omeros up 11% to $10.89 after AstraZeneca study failure

AZN

Jul 13, 2026, 2:16 PM EDT - 7 weeks ago

Omeros Corporation Investigated by the Portnoy Law Firm

Jun 26, 2026, 2:11 PM EDT - 2 months ago

Omeros stock crashes on regulatory setback: buy the dip?

2026-06-26T15:30:11.000Z - 2 months ago

Omeros price target lowered to $33 from $40 at H.C. Wainwright

2026-06-26T12:35:20.000Z - 2 months ago

Omeros announces CHMP adopts negative opinion on MAA for narsoplimab

Jun 26, 2026, 8:30 AM EDT - 2 months ago

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

Jun 18, 2026, 1:00 PM EDT - 2 months ago

Omeros Transcript: AGM 2026

Jun 15, 2026, 8:30 AM EDT - 2 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

2026-06-12T13:45:42.000Z - 2 months ago

Omeros trading resumes

2026-06-12T13:35:42.000Z - 2 months ago

Omeros trading halted, volatility trading pause

May 13, 2026, 4:30 PM EDT - 3 months ago

Omeros Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Omeros Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Omeros Quarterly report: Q1 2026

2026-05-13T20:27:08.000Z - 3 months ago

Omeros reports Q1 adjusted EPS (24c), consensus (28c)

May 13, 2026, 4:02 PM EDT - 3 months ago

Omeros Corporation Reports First Quarter 2026 Financial Results

May 11, 2026, 4:02 PM EDT - 4 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

2026-05-04T12:45:05.000Z - 4 months ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

KYTX

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Omeros Proxy statement: Proxy filing

2026-04-16T14:14:18.000Z - 4 months ago

Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA

Apr 16, 2026, 8:45 AM EDT - 4 months ago

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Earnings release: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Annual report: Q4 2025

2026-03-31T20:05:48.000Z - 5 months ago

Omeros reports Q4 EPS $1.22, consensus 36c

Mar 31, 2026, 4:02 PM EDT - 5 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Mar 26, 2026, 8:45 AM EDT - 5 months ago

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Mar 21, 2026, 3:23 AM EDT - 5 months ago

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

2026-02-17T14:15:38.000Z - 7 months ago

Omeros announces completion of nonhuman primates OncotoX-AML study

Feb 17, 2026, 8:45 AM EST - 7 months ago

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Jan 27, 2026, 9:00 AM EST - 7 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 7, 2026, 6:50 PM EST - 8 months ago

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 4:30 PM EST - 8 months ago

Omeros Transcript: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 8 months ago

Omeros Press release: FDA Announcement

Dec 26, 2025, 6:36 PM EST - 8 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 24, 2025, 9:05 AM EST - 8 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:00 AM EST - 8 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 1, 2025, 8:30 AM EST - 9 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Nov 13, 2025, 4:30 PM EST - 10 months ago

Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Omeros Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Omeros Earnings release: Q3 2025

Nov 13, 2025, 4:11 PM EST - 10 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 8:30 AM EST - 10 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Oct 16, 2025, 8:30 AM EDT - 11 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 15, 2025, 11:54 AM EDT - 11 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 9:17 AM EDT - 11 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Oct 15, 2025, 8:32 AM EDT - 11 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Oct 15, 2025, 8:30 AM EDT - 11 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Sep 2, 2025, 8:45 AM EDT - 1 year ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q2 2025

Aug 14, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 1 year ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

May 30, 2025, 8:00 AM EDT - 1 year ago

Omeros Proxy statement: Proxy Filing

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 1 year ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 1 year ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 10, 2025, 9:10 AM EDT - 1 year ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 1 year ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q4 2024

Mar 31, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

MrLucky123 Sep. 1 at 2:57 PM

$OMER continues to trade very well

0 · Reply

Polanc Sep. 1 at 1:52 PM

$OMER it wants to go up!

1 · Reply

StatsGuru Sep. 1 at 10:49 AM

$OMER today is going to be bulls day!!

0 · Reply

Phase3 Sep. 1 at 3:27 AM

$OMER .......

0 · Reply

uptech Sep. 1 at 1:30 AM

0 · Reply

Phase3 Sep. 1 at 12:30 AM

1 · Reply

MrLucky123 Aug. 31 at 10:24 PM

$OMER brutal month for the shorts, more to come. Come on GD let's get that NVO $ and EMA

1 · Reply

uptech Aug. 31 at 9:28 PM

1 · Reply

TRYII Aug. 31 at 9:02 PM

0 · Reply

StockMktGuru Aug. 31 at 8:51 PM

2 · Reply

capntrps Aug. 31 at 8:35 PM

$OMER interesting close. Will have to see on a better chart(vs phone).

0 · Reply

Abaco24 Aug. 31 at 8:34 PM

$OMER Peter Cancelmo - OMER VP and General Counsel just sold 25K shares and pocketed $463K

1 · Reply

MrLucky123 Aug. 31 at 8:29 PM

$OMER still see $21.40 near term. $18.40 buyer

0 · Reply

Ich_bin_ein_BerlOMER Aug. 31 at 8:14 PM

$OMER Who is ready for 20+ ???!!!

2 · Reply

uptech Aug. 31 at 7:41 PM

$OMER The Green Machine is back. Shaking off weak hands all day.

0 · Reply

Mountaineer Aug. 31 at 6:32 PM

$OMER No serious market participant is shorting on a couple of 105b sales. Get real, XBI has been weak af last few days. The end.

0 · Reply

Juststartingout14 Aug. 31 at 3:42 PM

$OMER gross proceeds 50k! And people think that’s a reason to short😂 Well, we do need the shorts to rocket so welcome abroad and thank you for your service!

0 · Reply

StatsGuru Aug. 31 at 1:32 PM

$OMER GD is going to burn all the shorts!

0 · Reply

Fmyl54 Aug. 31 at 12:30 PM

$OMER CS is very very

1 · Reply

rongside Aug. 31 at 7:40 AM

$OMER Worry about minor sales by directors is misguided. What is important is that our new director Joseph L. Schocken was quite happy to buy 525,000 shares of Omeros in the open market (+ 30,000 options for becoming director). Smart money.

0 · Reply

StatsGuru Aug. 31 at 2:13 AM

$OMER Into 20s and beyond this week!!

0 · Reply

SteadyasSheGoes Aug. 29 at 5:50 PM

$OMER Hard to believe that 2 months ago we were under $9. Thinking much more to go here! Continue to add on any pullback while selling puts and calls along the way! No extra charge...for those concerned about the execs cashing in options, remember, they can not trade on insider information. The recent insider sales are nothing burgers.

1 · Reply

Market Cap	1.35B
Revenue (ttm)	0.00
Net Income (ttm)	-3.35M
EPS (ttm)	N/A
PE Ratio	7.05
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-1.89

Volume	1,330,400
Avg Vol	2,048,000
Day's Range	N/A - N/A
Shares Out	72.39M
Stochastic %K	66%
Beta	2.54
Analysts	Sell
Price Target	$44.00